111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
利奈唑胺致晚期妇科肿瘤患者无症状性低血糖 1 例报告及文献复习
Received 4 July 2025
Accepted for publication 27 November 2025
Published 10 December 2025 Volume 2025:18 Pages 1575—1583
DOI https://doi.org/10.2147/IMCRJ.S551584
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Gates Colbert
Li Sun, Hongyu Fan, Yongjun Li
Department of Hematology and Oncology, Puyang Traditional Chinese Medicine Hospital, Puyang, People’s Republic of China
Correspondence: Li Sun, Department of Hematology and Oncology, Puyang Traditional Chinese Medicine Hospital, No. 135 Shengli East Road Hualong District, Puyang, Henan, 457000, People’s Republic of China, Tel +86-13083896787, Email hkfeihong@sina.com
Abstract: Hypoglycemia is a rare but documented adverse effect of linezolid. We report a 72-year-old patient with late-stage gynecologic cancer and abdominal MRSA peritonitis, who developed persistent asymptomatic hypoglycemia after starting linezolid. The patient had type 2 diabetes on metformin-glibenclamide. Fasting blood glucose dropped to 2.08 mmol/L (reference: 3.9– 6.1 mmol/L) 1 day post-linezolid initiation; hypoglycemia persisted despite stopping oral hypoglycemics and administering dextrose, but normalized within 24 hours after linezolid discontinuation (replaced with tigecycline). Naranjo ADR Scale scoring (7 points) confirmed a “probable” causal link. We present dynamic glucose trends (reinforcing causality) and review linezolid-associated hypoglycemia literature. This case highlights the need for glucose monitoring in linezolid-treated patients, especially at high risks, even without diabetes or symptoms.
Keywords: therapeutic drug monitoring, drug safety, cancer, antibiotics, adverse drug reactions
Department of Hematology and Oncology, Puyang Traditional Chinese Medicine Hospital, Puyang, People’s Republic of China
Correspondence: Li Sun, Department of Hematology and Oncology, Puyang Traditional Chinese Medicine Hospital, No. 135 Shengli East Road Hualong District, Puyang, Henan, 457000, People’s Republic of China, Tel +86-13083896787, Email hkfeihong@sina.com
Abstract: Hypoglycemia is a rare but documented adverse effect of linezolid. We report a 72-year-old patient with late-stage gynecologic cancer and abdominal MRSA peritonitis, who developed persistent asymptomatic hypoglycemia after starting linezolid. The patient had type 2 diabetes on metformin-glibenclamide. Fasting blood glucose dropped to 2.08 mmol/L (reference: 3.9– 6.1 mmol/L) 1 day post-linezolid initiation; hypoglycemia persisted despite stopping oral hypoglycemics and administering dextrose, but normalized within 24 hours after linezolid discontinuation (replaced with tigecycline). Naranjo ADR Scale scoring (7 points) confirmed a “probable” causal link. We present dynamic glucose trends (reinforcing causality) and review linezolid-associated hypoglycemia literature. This case highlights the need for glucose monitoring in linezolid-treated patients, especially at high risks, even without diabetes or symptoms.
Keywords: therapeutic drug monitoring, drug safety, cancer, antibiotics, adverse drug reactions